• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Society of Photo-Optical Instrumentation Engineers;SPIE Medical Imaging Conference >Morphology of Vascular Network in Eyes with Diabetic Macular Edema Varies Based on Tolerance of Aibercept Treatment Interval Length: Preliminary Findings
【24h】

Morphology of Vascular Network in Eyes with Diabetic Macular Edema Varies Based on Tolerance of Aibercept Treatment Interval Length: Preliminary Findings

机译：基于A耐受性的糖尿病性黄斑水肿眼的血管网络形态变化ibercept治疗间隔时长：初步发现

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Diabetic macular edema is a leading cause of vision loss in diabetic patients.The underlying cause for the onsetof DME is 1) the long term presence of hyperglycemia and the eventual degradation of the blood-retinal barrier(BRB) via an uptick in vascular endothelial growth factor(VEGF); VEGF increases the permeability of the bloodretinal barrier and alters the length of capillaries, thereby inhibiting the ability of these vessels in performing theirprimary function of filtration. The lack of a proper filtration system in combination with the the ongoing changein intra-retinal vasculature that stems from it, results in the eventual loss of visual acuity in DME patients.Due to the large role in which VEGF plays in acting as a catalyst for the onset of DME, current treatments nowfocus on utilizing anti-VEGF therapy as a first line treatment for DME. Anti-VEGF therapy improves clinicaloutcomes in the form of improved visual acuity and reduction in macular edema. Anti-VEGF treatments alsohave a peripheral effect of modifying the disease burden and allowing for extended time in between treatments.However, there is still a void in understanding how anti-VEGF affects the underlying pathophysiology. This studyfocuses on using quantification of the geometric properties of vasculature on Fluorescein Angiography(FA) tounderstand the impact anti-VEGF treatment has on retinal vascular dynamics. We hypothesize that vasculaturedisorder, due to VEGF action, differs across patients and can be modeled mathematically to identify candidatesfor anti-VEGF treatment.We use VaNgOGH, a Hough transform-based descriptor to model the disorder of the retinal vascular networkon baseline FA of patients subsequently treated with intravitreal anti-VEGF therapy(aibercept). VaNgOGHcomputes local measures of vessel-curvature and identifies dominant peaks in the accumulator space. We exploredthe differences in such features on baseline FA between eyes tolerating extended dosing interval (N=15) and thoseeyes requiring more frequent dosing (N=12), based on initial response following treatment interval extension.The cross-validated AUC was found to be 0.73-0.1 using VaNgOGH. The variance of local orientationsshowed a statistically significant difference(p=0.008) between the two categories, unlike clinical parameters onbaseline OCT. Our results suggest there may be fundamental differences in localized vessel orientations betweeneyes that will exhibit favorable response to extended interval aibercept dosing and eyes that require morefrequent dosing.
机译：糖尿病性黄斑水肿是糖尿病患者视力下降的主要原因。 DME的症状是1）长期存在高血糖症并最终降解血视网膜屏障 （BRB）通过血管内皮生长因子（VEGF）的升高; VEGF增加血液的通透性 视网膜屏障并改变毛细血管的长度，从而抑制这些血管进行血管扩张的能力 过滤的主要功能。缺乏适当的过滤系统以及持续的变化 视网膜内脉管系统中的这种作用会导致DME患者最终失去视力。 由于VEGF在DME发作中起着重要作用，因此目前的治疗方法 专注于将抗VEGF治疗用作DME的一线治疗。抗VEGF治疗改善临床 以改善视力和减少黄斑水肿的形式预后。抗VEGF疗法也 具有改善疾病负担并延长治疗间隔时间的外围作用。 但是，了解抗VEGF如何影响潜在的病理生理学仍然存在空白。这项研究 专注于在荧光素血管造影（FA）上使用脉管系统的几何特性的量化 了解抗VEGF治疗对视网膜血管动力学的影响。我们假设脉管系统 由于VEGF的作用，该疾病因患者而异，可以通过数学建模来识别候选对象 用于抗VEGF治疗。 我们使用基于霍夫变换的描述符VaNgOGH来建模视网膜血管网络的疾病 玻璃体内抗VEGF治疗的患者的基线FA水平 ibercept）。瓦格 计算血管曲率的局部量度，并确定累加器空间中的主导峰。我们探索了 耐受延长给药间隔（N = 15）的眼睛与那些在基线FA上的特征之间的差异 根据治疗间隔延长后的初始反应，需要更频繁用药的眼睛（N = 12）。 使用VaNgOGH发现交叉验证的AUC为0.73-0.1。局部取向的变化 表现出两类之间的统计学显着性差异（p = 0.008），与 基线OCT。我们的结果表明， 对延长间隔a表现出良好反应的眼睛 ibercept剂量和需要更多的眼睛 经常加药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号